Explore (New York, N.Y.) · 2025
Unraveling cassia oil's efficacy in alleviating winter-triggered mood disorders in Parkinson's disease patients via aromatherapy-mediated pathways.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Qiang, Zhang Peilu, Yan Dongwei
Аннотация
OBJECTIVES: This randomized controlled trial (RCT) aimed to evaluate the efficacy of Cassia Oil (CO)-based fragrance therapy in alleviating winter-aggravated mood disorders (including depression and anxiety) in Parkinson's disease (PD) patients, specifically assessing its effects on improving sleep quality and reducing fatigue-key comorbid symptoms often exacerbated in winter. Additionally, it sought to verify whether this non-pharmacological intervention could serve as a viable complementary strategy for managing seasonal symptom fluctuations in PD.
METHODS: Eighty PD patients were randomized to receive CO inhalation therapy (2 h/day, 5 days/week for 8 weeks; n = 40) or standard care (n = 40). Outcomes included mood (Hamilton Depression Scale [HAMD], Hamilton Anxiety Scale [HAMA]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), fatigue (Fatigue Scale-14 [FS-14]). Assessments were conducted at baseline and post-treatment.
RESULTS: The intervention group demonstrated significant reductions in HAMD (22.08±5.43 vs. 13.65±2.73, p < 0.01) and HAMA scores (17.63±4.50 vs. 12.23±0.53, p < 0.001), with no changes in controls (HAMD: 22.87±6.03 to 23.38±5.66, p = 0.72; HAMA: 16.93±3.87 to 15.95±4.55, p = 0.31). PSQI total scores improved significantly in the intervention group (12.20±3.09 to 0.83±0.96, p < 0.01), particularly in subjective sleep quality (t = 6.55, p < 0.01) and sleep latency (t = 5.46, p < 0.01).
CONCLUSION: CO-based fragrance therapy effectively improved mood, sleep quality, and fatigue in PD patients during winter, offering a novel non-pharmacological approach for seasonal symptom management.
METHODS: Eighty PD patients were randomized to receive CO inhalation therapy (2 h/day, 5 days/week for 8 weeks; n = 40) or standard care (n = 40). Outcomes included mood (Hamilton Depression Scale [HAMD], Hamilton Anxiety Scale [HAMA]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]), fatigue (Fatigue Scale-14 [FS-14]). Assessments were conducted at baseline and post-treatment.
RESULTS: The intervention group demonstrated significant reductions in HAMD (22.08±5.43 vs. 13.65±2.73, p < 0.01) and HAMA scores (17.63±4.50 vs. 12.23±0.53, p < 0.001), with no changes in controls (HAMD: 22.87±6.03 to 23.38±5.66, p = 0.72; HAMA: 16.93±3.87 to 15.95±4.55, p = 0.31). PSQI total scores improved significantly in the intervention group (12.20±3.09 to 0.83±0.96, p < 0.01), particularly in subjective sleep quality (t = 6.55, p < 0.01) and sleep latency (t = 5.46, p < 0.01).
CONCLUSION: CO-based fragrance therapy effectively improved mood, sleep quality, and fatigue in PD patients during winter, offering a novel non-pharmacological approach for seasonal symptom management.